Efruxifermin for NASH
Trial Summary
Do I need to stop my current medications for the Efruxifermin for NASH trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Efruxifermin for NASH?
How is the drug Efruxifermin unique for treating NASH?
Efruxifermin is unique because it is a fusion protein that combines a part of the human antibody with FGF21, a protein that helps regulate metabolism, and it specifically targets liver fibrosis in NASH, a condition with no approved treatments. Its mechanism involves binding to a specific receptor on cells to activate pathways that may reduce liver damage.56789
What is the purpose of this trial?
This trial is testing a medication called efruxifermin (EFX) to see if it can help people with specific liver conditions. These conditions are hard to treat with current methods. EFX aims to improve liver health by reducing inflammation and fat buildup in the liver.
Eligibility Criteria
This trial is for adults aged 18-80 with a suspected or confirmed diagnosis of NASH/MASH or NAFLD/MASLD, and who have at least two components of metabolic syndrome or type 2 diabetes. It's not open to those with other liver diseases, type 1 diabetes, or unstable type 2 diabetes.Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Efruxifermin or placebo for the assessment of safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Efruxifermin
Find a Clinic Near You
Who Is Running the Clinical Trial?
Akero Therapeutics, Inc
Lead Sponsor